Open-label phase 3 trial in 148 children aged 2-17 with PAH: macitentan PK matched adults; disease progression (HR 0.828), PAH hospitalisation and mortality did not differ significantly from standard of care, though quality of life improved.
RCTn = 148
Berger et al. Macitentan in Pediatric Pulmonary Arterial Hypertension (TOMORROW): A Randomized Clinical Trial